Register free now:

Sign Up:

Title *

* Required

First name *

* Required

Last name *

* Required

Business email *

* Required

Company *

* Required

Address line 1 *

* Required

Address line 2

* Required

City *

* Required

State/Province *

* Required

Postcode/Zipcode *

* Required

Country *

* Required

Business telephone *

* Required

Position *

* Required

Field *

* Required

Discipline *

* Required

Would you like more information about the technologies featured in this webinar? *

YesNo * Required

Note: By completing this form, you will receive a free membership to SelectScience and The Scientists’ Channel. SelectScience^® is a trade organisation, we do not provide services to consumers and membership is for business purposes only. As a member you must provide us with a corporate email address to enable us (and our advertisers and sponsors) to contact you for marketing purposes. You can opt-out of marketing at any time. See our Privacy Policy*

* Required

(*) denotes required form field(s)

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

IVDR: Understanding the transitional provisions

Available On-Demand

As the countdown begins to the EU IVDR date of application, are you aware of which requirements will apply to all devices starting May 2022, and what updated transitional arrangements will apply to certain products?

There have been several factors that have contributed to health institutions and companies being unable to comply with the new requirements coming into effect on the 26 May 2022; however, the extension of the transitional arrangements does not apply uniformly across all in vitro diagnostics (IVDs) and is not a delay to the date of application.

Join Sue Spencer, Principal Consultant at Qserve Group, Erik Vollebregt, Partner at Axon Lawyers, and Dr. Julien Senac, Global Director of the IVD Focus Team at TÜV SÜD, for more details on the transitional arrangements, whether and how your IVD might be impacted, and how to comply with these additional provisions.

Key learning objectives

What is the change to the transitional arrangements for IVDR?
What is the status of notified bodies and application for approval of new devices?
What are the economic operator obligations for legacy devices?
Does the Clinical Trial Regulation apply to IVDs or IVDs used in clinical trials?

Who should attend?

Stakeholders in molecular diagnostics, IVD manufacturers and clinical labs globally. Segments would include:

R&D staff (decision makers)

Quality staff

Operational staff

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

Speakers:

Sue Spencer

Head of In Vitro Diagnostics & Principal Consultant
Qserve Group
View Biography

Erik Vollebregt

Partner
Axon Lawyers
View Biography

Dr. Julien Senac

Director of Medical and Health services
TUV SUD Americas
View Biography

Moderator: Cameron Smith-Craig

Editorial Team
SelectScience
View Biography